Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Laryngeal and hypopharyngeal cancer, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Hypopharyngeal cancer survival has barely improved.
Choosing between preservation and laryngectomy in T4 disease.
Long-term swallowing and airway function after chemoradiation.
Persistently high incidence where smoking remains common.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
OS 14.
A milestone in how this cancer is treated.
Median overall survival 49.
Larynx preservation at 2 years 88% (concurrent) vs 75% (induction) vs 70% (radiotherapy alone).
A milestone in how this cancer is treated.